Abaloparatide
Tymlos (PTHrP analog)
Abaloparatide (Tymlos (PTHrP analog)) is a healing & recovery research compound. PTHrP(1-34) analog — intermittent daily dosing preferentially drives osteoblast bone formation; newer sibling to teriparatide with less hypercalcemia risk.
Abaloparatide quick facts
| Reported research dose | 80mcg |
| Route | Subq |
| Frequency | 1x Daily |
| Half-life | ~1.7 hrs |
| Forms | Injectable |
| Evidence level | FDA-approved (osteoporosis) |
Bone-builder — the more selective, lower-side-effect version of teriparatide.
How Abaloparatide works
PTHrP(1-34) analog — intermittent daily dosing preferentially drives osteoblast bone formation; newer sibling to teriparatide with less hypercalcemia risk.
Proposed benefits
Researched for soft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
Can you actually get Abaloparatide?
Same specialist channel as teriparatide — a bone clinic, not a direct-to-consumer service.
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Abaloparatide
Graded by what exists behind each claim.
✅ Clinically validated
- FDA-approved for osteoporosis on the ACTIVE trial, which showed an 86% reduction in new vertebral fractures against placebo and greater bone mineral density gains than teriparatide at the hip.
📊 Correlative data
- Prescription-only clinical use in osteoporosis. Essentially no community use, and no route to obtain it outside a prescriber.
🧪 Theoretical / extrapolated
- A PTHrP analog that binds the PTH1 receptor with a preference for the transient RG conformation rather than the prolonged RG0 state teriparatide favors.
- That receptor-binding difference is the proposed mechanism for its more anabolic, less resorptive profile — more bone building relative to bone breakdown. Like all PTH-pathway agents it requires intermittent dosing: continuous PTH signaling *removes* bone.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Abaloparatide actually does
The interesting thing about abaloparatide is not which receptor it hits. It is which shape of that receptor it prefers. The PTH type 1 receptor exists in two ligand-binding conformations: R0, which binds ligand tightly and keeps signaling after the G protein has uncoupled, and RG, the G-protein-coupled state that produces a shorter, sharper burst of cyclic AMP. Teriparatide, which is PTH(1-34), engages both. Hattersley 2016 showed abaloparatide binds with greater selectivity to the RG conformation, and that as a direct result of this RG bias it produces more transient cAMP responses.
Why transience is the whole drug. The PTH1 receptor is the textbook case of a signal whose pattern determines its direction. Continuous PTH1R signaling — primary hyperparathyroidism — drives RANKL, recruits osteoclasts and dissolves bone. Intermittent signaling, the same receptor stimulated in short pulses, favors osteoblast survival and matrix deposition and builds bone. So a daily injection of any PTH1R agonist is a bet that the exposure is brief enough to land on the anabolic side of that line. RG bias is a molecular way of making a given injection more intermittent than the clock alone would make it, and that is the proposed mechanism for a more anabolic, less resorptive profile.
The prediction that mechanism makes, and the number that tests it. Prolonged R0-mediated signaling is what mobilizes calcium from bone and holds it up. An RG-biased ligand should therefore produce less hypercalcemia at equal anabolic effect. In the head-to-head trial, hypercalcemia occurred in 3.4% on abaloparatide versus 6.4% on teriparatide, a risk difference of −2.96 (95% CI −5.12 to −0.87, p = 0.006) Miller 2016. That is the receptor-conformation story showing up in a clinical chemistry value, which is about as good as mechanism-to-human ever gets.
One thing it is not. Abaloparatide is an analog of parathyroid hormone-related protein rather than of PTH itself, and PTHrP is a locally acting factor in cartilage and bone rather than a calcium-regulating hormone. That difference is real chemistry, but it does not make the compound gentler in the way the marketing implies — the receptor is the same receptor, and the rat carcinogenicity data in the safety section show exactly how far the ‘gentler sibling’ framing can be pushed.
Cell, rodent, human — and where it stops
In cells. Conformational binding assays and cAMP time-courses at the human PTH1 receptor: RG-selective binding, more transient signaling than PTH(1-34) Hattersley 2016.
In rodents, and this is a two-year study, not a two-week one. Fischer rats received abaloparatide or hPTH(1-34) by daily subcutaneous injection for up to 2 years. Robust increases in bone density were achieved at all abaloparatide doses and with hPTH(1-34) Jolette 2017. The efficacy signal in rodents is unambiguous; what else that study found is in the safety section, and it is the more important half.
In humans: the ACTIVE trial, and it is a large, clean, registered study. Miller 2016 randomized 2,463 postmenopausal women at 28 centers in 10 countries for 18 months to abaloparatide 80 mcg subcutaneously daily (n = 824), placebo (n = 821), or open-label teriparatide 20 mcg (n = 818). Primary endpoint: new vertebral fractures. Result: 0.6% (4/824) on abaloparatide versus 4.2% (30/821) on placebo, relative risk 0.14 (95% CI 0.05–0.39), p < 0.001. It met its primary endpoint. Nonvertebral fractures fell too, 2.7% versus 4.7%, hazard ratio 0.57 (0.32–1.00), p = 0.049. Bone mineral density at 18 months rose 4.18% at the total hip, 3.60% at the femoral neck and 11.20% at the lumbar spine, against −0.10%, −0.43% and 0.63% on placebo.
Now read the comparison everyone quotes, carefully. Against teriparatide, abaloparatide gained more at hip and femoral neck (4.18% vs 3.26%; 3.60% vs 2.66%) and produced less hypercalcemia. On the endpoint that matters — nonvertebral fracture — the difference was 2.7% versus 3.3%, hazard ratio 0.79, p = 0.44. Not significant. So “better than teriparatide” is supported on hip density and on calcium safety, and is not supported on fractures, and the teriparatide arm was open-label rather than blinded Miller 2016.
The obstacles. (1) The entire human evidence base is postmenopausal women with osteoporosis at high fracture risk. Nothing in it describes a healthy adult, a male athlete, or anyone using it for tissue repair. (2) There is no trial of abaloparatide for fracture healing, tendon or ligament repair — the indication is fracture prevention through bone density, which is a different biology from healing a break faster. (3) The gains are not durable on their own: this is an 18-month anabolic course that needs an antiresorptive afterwards to hold what it built. (4) The label itself states that safety and efficacy have not been evaluated beyond 2 years, and that use for more than 2 years in a lifetime is not recommended US Food and Drug Administration 2023.
Abaloparatide pharmacokinetics — how much of it actually gets in
Route: subcutaneous, from a pre-filled pen — there is no reconstitution step and no diluent involved. The dose is 80 mcg once daily US Food and Drug Administration 2023.
The numbers, from the label. Absolute bioavailability 36%. Median Tmax 0.51 hours (range 0.25 to 0.52). Mean half-life approximately 1 hour. Volume of distribution approximately 50 L. Protein binding approximately 70% US Food and Drug Administration 2023. Note that the half-life on this site's own card reads ~1.7 hours; the approved labeling says about 1 hour, and the shorter number is the one the mechanism depends on.
What degrades it: nothing exotic. The label describes non-specific proteolytic degradation into smaller peptide fragments, with elimination primarily by renal excretion US Food and Drug Administration 2023. There is no cytochrome P450 involvement, which means the usual drug-interaction anxieties do not apply — and it also means that in significant renal impairment the fragments, and any residual peptide, clear more slowly.
Why a one-hour half-life is the therapeutic mechanism rather than a limitation. Peak at half an hour, gone within a few hours: the receptor sees a spike and then nothing for twenty hours. That is precisely the intermittent exposure that pushes PTH1R signaling toward bone formation, and it is why nobody has ever made a sustained-release version of this class for osteoporosis — a depot would recreate hyperparathyroidism and dissolve the bone it was meant to build. Abaloparatide's RG-biased binding makes each of those spikes shorter still at the level of the receptor Hattersley 2016. The 36% bioavailability is not a problem to be engineered away either; the dose was chosen with it.
There is no oral form and there will not be a simple one. A 34-residue peptide meets gastric acid and the whole pancreatic protease set, and its first-pass survival is effectively zero. Every human efficacy number on this page belongs to a subcutaneous injection.
What would have to be true, and how you would know it was not
1. Serum calcium should rise transiently after each dose, and the timing is specific. Peak drug at about 30 minutes, so check albumin-corrected calcium on a CMP roughly 4 hours after a dose, not at a fasting morning draw when the drug is long gone. Label incidence of hypercalcemia is 3% versus 0.1% on placebo US Food and Drug Administration 2023. Prediction: a small post-dose rise in nearly everyone and a persistent pre-dose elevation in almost nobody. A high pre-dose calcium is the abnormal finding and the one that means stop.
2. Bone formation markers should move within one quarter. Osteocalcin at baseline and at 3 months. This is an anabolic agent; formation markers rise before density changes are measurable, and DXA cannot resolve anything meaningful before 12 months. If osteocalcin has not risen by month 3, the drug is not doing the thing it is for — and that is detectable nine months before the scan would show it.
3. The prediction that cuts against it: urine calcium should rise, and stones are a labeled risk. Hypercalciuria and urolithiasis are named Warnings and Precautions US Food and Drug Administration 2023. So a urinalysis plus a 24-hour urine calcium at baseline and month 3, particularly in anyone with a stone history. Prediction: urine calcium rises measurably even in people whose serum calcium never leaves the reference range. Serum calcium is the reassuring number; urine calcium is the informative one.
4. Orthostatic hypotension should show up in the first four hours of the first few doses, then fade. The label reports dizziness in 10% versus 6% and palpitations in 5% versus 0.4% US Food and Drug Administration 2023. Concretely: lying and standing blood pressure before, and 1 and 4 hours after, dose 1 and dose 5, taken at home. Prediction — a measurable postural drop early that attenuates with repeated dosing, which is why the label's advice is to take the first doses where you can sit or lie down.
5. And the baseline check on the PTH-calcium axis. Vitamin D and PTH at baseline, because an undiagnosed primary hyperparathyroidism or a vitamin D deficiency changes both the safety and the response, and neither is rare in the population this drug is prescribed to.
What nobody has tested yet
Nobody has tested abaloparatide for healing anything. It sits in this site's recovery category, and its entire human evidence base is fracture prevention in osteoporotic postmenopausal women Miller 2016. Whether a PTH1R agonist accelerates union of an existing fracture, or does anything for tendon or ligament, is an open question with a straightforward design: a randomized trial in acute distal radius fracture with radiographic union time as the endpoint. The biology is plausible enough that the trial should exist; it does not.
Nobody has run a fracture-powered head-to-head against teriparatide. ACTIVE was powered against placebo; its teriparatide arm was open-label and the nonvertebral fracture comparison was not significant (p = 0.44) Miller 2016. Every claim that abaloparatide is the better anabolic rests on hip density and hypercalcemia rates. A blinded, fracture-powered comparison would settle a decision clinicians make every week.
Nobody has shown that RG bias produces a human benefit beyond calcium. Hattersley 2016 is a receptor-pharmacology result, and the one clinical correlate anyone has connected to it is the lower hypercalcemia rate. Whether transient signaling also changes the formation-to-resorption ratio measurably in people — paired P1NP and CTX time-courses after a single dose of each drug, in the same subjects — is a one-day crossover study nobody has published.
And nobody knows what the abaloparatide-specific long-term cancer picture looks like. Teriparatide accumulated fifteen years of post-marketing osteosarcoma surveillance before its boxed warning was removed Krege 2022. Abaloparatide was approved in 2017 and carries a fraction of that exposure. The warning came off both drugs together; the evidence behind the two removals is not equivalent.
Abaloparatide — its own safety story, not its class's
The black box, and what actually happened to it. Abaloparatide came to market carrying a boxed warning for risk of osteosarcoma, based on rat carcinogenicity, together with a recommendation not to exceed two years of cumulative use. The current labeling has no boxed warning: osteosarcoma now appears as an ordinary Warning and Precaution alongside orthostatic hypotension, hypercalcemia, and hypercalciuria and urolithiasis US Food and Drug Administration 2023. That change followed the same reassessment that removed teriparatide's boxed warning after roughly fifteen years of post-marketing osteosarcoma surveillance failed to show the rat signal in people Krege 2022.
Read the rat data before you decide the story is over, because it does not say what most summaries imply. Jolette 2017 dosed Fischer rats daily for up to two years with abaloparatide or hPTH(1-34) and found a comparable continuum of proliferative bone changes, mostly osteosarcoma, in both. Comparing equidistant doses gave similar osteosarcoma-associated mortality, similar tumor incidence and a similar age at first occurrence. Abaloparatide was not the cleaner molecule in the rat. The label states it plainly: a dose-dependent increase in osteosarcoma in male and female rats at exposures 4 to 28 times the human exposure at 80 mcg US Food and Drug Administration 2023. The warning came off because the human surveillance reassured, not because this compound's animal data were better.
What the 2-year statement still says. The current label: safety and efficacy have not been evaluated beyond 2 years of treatment, and use for more than 2 years during a patient's lifetime is not recommended US Food and Drug Administration 2023 — a limit the original 2017 boxed warning applied to cumulative use of TYMLOS and parathyroid hormone analogs such as teriparatide combined, not to each drug separately. That is not a formality — it is the boundary of the entire human dataset, and it is the reason this is a course rather than a maintenance drug.
The everyday adverse effects, with the label's own numbers. Versus placebo over 18 months in postmenopausal women: injection-site redness 58% vs 28%, dizziness 10% vs 6%, nausea 8% vs 3%, palpitations 5% vs 0.4%, hypercalcemia 3% vs 0.1% US Food and Drug Administration 2023. The palpitations and dizziness cluster in the hours after a dose and are the practical reason for taking the first ones sitting down.
Who should not be near it. The osteosarcoma warning is directed at people with an already-raised baseline risk of the tumor — Paget disease of bone, unexplained elevations of alkaline phosphatase, prior skeletal radiation, open epiphyses, or bone metastases US Food and Drug Administration 2023. Open epiphyses is the one worth stating loudly on a site like this: a skeletally immature person is exactly the wrong person for a PTH1R anabolic.
Sources read for this page
- Miller PD. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.. JAMA 2016 · PMID 27533157
- Hattersley G. Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.. Endocrinology 2016 · PMID 26562265
- Jolette J. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34).. Regul Toxicol Pharmacol 2017 · PMID 28389324
- Krege JH. Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates.. JBMR Plus 2022 · PMID 36111201
- US Food and Drug Administration. TYMLOS (abaloparatide) injection - full prescribing information.. FDA approved labeling, revision 2023
Abaloparatide — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Abaloparatide — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Abaloparatide moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
The honest position on this class is that the proliferation question is unresolved — anything that accelerates tissue repair is acting on pathways cancer also uses. Nobody has studied it properly either way.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Abaloparatide in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Abaloparatide
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
Abaloparatide — frequently asked questions
What is Abaloparatide?
Abaloparatide (Tymlos (PTHrP analog)) is a healing & recovery research compound. PTHrP(1-34) analog — intermittent daily dosing preferentially drives osteoblast bone formation; newer sibling to teriparatide with less hypercalcemia risk.
Is the full Abaloparatide protocol on this page?
The reported research dose is on this page, along with how Abaloparatide works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Abaloparatide?
Abaloparatide has an approximate half-life of ~1.7 hrs, which is part of what determines how often it's dosed.
What's the evidence behind Abaloparatide?
Current evidence level: FDA-approved (osteoporosis). Abaloparatide is offered for research purposes only and is not an approved medicine.
What Abaloparatide is used for
Abaloparatide appears under 2 goals in the goal router.
Related Healing & Recovery compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.